secwatch.observer — SEC 8-K summary
======================================

Issuer:     Compass Therapeutics, Inc. (CMPX)
CIK:        0001738021
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001171843-23-004946
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Compass Therapeutics Q2 net loss $11.3M; BTC top-line data pushed to H2 2024
----------------------------------------------------------------------------

- Net loss of $11.3M ($0.09/share) in Q2 2023 vs $8.5M loss ($0.08/share) in Q2 2022.
- Cash and marketable securities $169M as of June 30, 2023; cash runway into 2026.
- R&D expense $10.2M in Q2 2023, up 74% YoY driven by CTX-009 clinical and manufacturing costs.
- CTX-009 Phase 2 CRC initial data still expected H2 2023; BTC top-line data delayed to H2 2024 due to slower enrollment.
- CTX-8371 (PD-1 x PD-L1) IND submission targeted Q3 2023 with Phase 1 start in Q4 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1738021/000117184323004946/0001171843-23-004946-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1738021/000117184323004946/f8k_080223.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-004946

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer